ZRSEF Stock Chart & Stats
$5.32
--
Market closed
$5.32
--
Day’s Range― - ―
52-Week Range$4.68 - $11.14
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$549.79M
Enterprise Value$581.69M
Total Cash (Recent Filing)$149.92M
Total Debt (Recent Filing)$288.64M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding52,400,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue0.52
Enterprise Value/Gross Profit5.50
Enterprise Value/Ebitda-14.77
Forecast
1Y Price Target
$8.08Price Target Upside51.93% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-2.22
Revenue Forecast (FY)$1.52B
Bulls Say, Bears Say
Bulls Say
Platform Scale And Customer MetricsA large and growing active customer base (≈11m) with improving order frequency and retention provides a durable revenue foundation. Recurring Rx demand and higher AOV allow fixed logistics and tech costs to be amortized, supporting sustainable unit economics as scale grows.
High-margin Digital Services ExpansionRapid, high-margin digital services (TeleClinic, Retail Media) diversify revenue away from low-margin Rx retail. Their scale and take-rate economics materially lift CM3 and overall margins, creating a structural profitability lever as penetration increases and fixed costs are spread.
Improved Liquidity And LeverageStronger year-end liquidity and a markedly improved equity ratio reduce immediate refinancing pressure and give management runway to execute margin initiatives and digital investments. Lower net debt improves flexibility to convert growth initiatives into profitable outcomes.
Bears Say
Consistent Negative Operating And Free Cash FlowSustained and worsening cash burn materially weakens financial flexibility. Persistent negative OCF/FCF forces reliance on external funding or asset sales to sustain operations, constrains reinvestment, and raises execution risk for the staged path to FCF breakeven in 2027.
Ongoing Losses And Weak ProfitabilityRepeated negative margins and substantial adjusted EBITDA losses mean returns on capital remain negative and equity value creation is absent. This prolongs dependence on financing, undermines ability to invest in growth sustainably, and raises downside if margin recovery stalls.
Working-capital And Operational Cost InefficienciesMaterial working-capital mismanagement and receivables problems increase cash conversion risk and inflate financing needs. Coupled with elevated logistics and marketing costs, these structural inefficiencies can erode margins and require persistent operational fixes to stabilize cash flow.
ZRSEF FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was $4.68 and its highest was $11.14 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is $549.79M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Aug 19, 2026 which is in 40 days.
How were DocMorris AG’s earnings last quarter?
Currently, no data Available
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Undervalued.
Does DocMorris AG pay dividends?
DocMorris AG pays a Annually dividend of $0.518 which represents an annual dividend yield of N/A. See more information on DocMorris AG dividends here
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 52,400,000 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in ZRSEF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
ZRSEF Stock 12 Month Forecast
Average Price Target
$8.08
▲(51.93% Upside)
Ownership Overview
―
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---